BAY2666605 for Metastatic Melanoma and Other Solid Tumors
Study Summary
This trial is being done to learn more about a new substance called BAY2666605 that may help treat advanced cancer by triggering cell death.
- Metastatic Melanoma and Other Solid Tumors
Treatment Effectiveness
Study Objectives
7 Primary · 5 Secondary · Reporting Duration: Up to 28 + 14 days
Trial Safety
Trial Design
2 Treatment Groups
Dose expansion of BAY2666605
1 of 2
Dose escalation of BAY2666605
1 of 2
Experimental Treatment
89 Total Participants · 2 Treatment Groups
Primary Treatment: BAY2666605 · No Placebo Group · Phase 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:About The Reviewer
Michael Gill - B. Sc.
First Published: October 26th, 2021
Last Reviewed: November 3rd, 2022
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.